First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non–Small-Cell Lung Cancer

Jill S. Remick, Caitlin Schonewolf, Peter Gabriel, Abigail Doucette, William P. Levin, John C. Kucharczuk, Sunil Singhal, Taine T.V. Pechet, Ramesh Rengan, Charles B. Simone, Abigail T. Berman

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Abstract

We investigated the survival outcomes and early toxicity profile of postoperative radiation therapy with proton beam therapy (PBT) versus intensity-modulated radiation therapy (IMRT) for non–small-cell lung cancer (NSCLC) in a cohort of 61 patients with positive microscopic margins and/or positive N2 lymph nodes. We found that postoperative PBT in locally advanced NSCLC is well-tolerated and has similar excellent short-term outcomes when compared with IMRT. Background and Purpose The characteristic Bragg peak of proton beam therapy (PBT) allows for sparing normal tissues beyond the tumor volume that may allow for decreased toxicities associated with postoperative radiation therapy (PORT). Here we report the first institutional experience with proton therapy for PORT in patients with non–small-cell lung cancer (NSCLC) and assess early toxicities and outcomes. Materials and Methods We identified 61 consecutive patients treated from 2011 to 2014 who underwent PORT for locally advanced NSCLC for positive microscopic margins and/or positive N2 lymph nodes (stage III), with 27 patients receiving PBT and 34 receiving intensity-modulated radiation therapy (IMRT). Results Median follow-up time was 23.1 months for PBT (2.3-42.0 months) and 27.9 months for IMRT (0.5-87.4 months). The median radiation dose was 50.4 Gy for PBT (50.4-66.6 Gy) and 54 Gy for IMRT (50.0-72.0 Gy). Grade 3 radiation esophagitis was observed in 1 and 4 patients in the PBT and IMRT groups, respectively. Grade 3 radiation pneumonitis was observed in 1 patient in each cohort. Dosimetric analysis revealed a significant decrease in the V5 and mean lung dose (P = .001 and P = .045, respectively). One-year median overall survival and local recurrence-free survival were 85.2% and 82.4% (95% confidence interval, 72.8%-99.7% and 70.5%-96.2%, P = .648) and 92.3% and 93.3% (82.5%-100%, 84.8%-100%, P = .816) for PBT and IMRT cohorts, respectively. Conclusions Postoperative PBT in NSCLC is well-tolerated and has similar excellent short-term outcomes when compared with IMRT. Longer follow-up is necessary to determine if PBT has a meaningful improvement over IMRT for PORT.

Original languageEnglish
Pages (from-to)364-371
Number of pages8
JournalClinical Lung Cancer
Volume18
Issue number4
DOIs
StatePublished - Jul 2017

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Non-Small-Cell Lung/mortality
  • Esophagitis/etiology
  • Female
  • Follow-Up Studies
  • Humans
  • Lung Neoplasms/mortality
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Pneumonectomy
  • Proton Therapy/adverse effects
  • Radiation Injuries
  • Radiotherapy Dosage
  • Radiotherapy, Intensity-Modulated/adverse effects
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non–Small-Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this